---
title: "RKT: H1 2026 net revenue up 2.6% to £6,411m; strong emerging market growth and £3bn+ cash returned"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294179467.md"
description: "H1 2026 net revenue rose 2.6% year-over-year to £6,411m, with emerging markets and innovation driving growth. Adjusted operating profit margin was 23.6%, and over £3bn was returned to shareholders. FY 2026 guidance is reiterated, targeting 4–5% LFL net revenue growth.Original document: Reckitt Benckiser Group plc [RKT] Slides Release — Jul. 29 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-29T09:05:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294179467.md)
  - [en](https://longbridge.com/en/news/294179467.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294179467.md)
generator: "portal-rs"
---

# RKT: H1 2026 net revenue up 2.6% to £6,411m; strong emerging market growth and £3bn+ cash returned

H1 2026 net revenue rose 2.6% year-over-year to £6,411m, with emerging markets and innovation driving growth. Adjusted operating profit margin was 23.6%, and over £3bn was returned to shareholders. FY 2026 guidance is reiterated, targeting 4–5% LFL net revenue growth.

Original document: Reckitt Benckiser Group plc \[RKT\] Slides Release — Jul. 29 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [RBGLY.US](https://longbridge.com/en/quote/RBGLY.US.md)
- [RKT.UK](https://longbridge.com/en/quote/RKT.UK.md)
- [RBGLD.US](https://longbridge.com/en/quote/RBGLD.US.md)

## Related News & Research

- [Reckitt unit Mead Johnson draws USD 400.42 million tenders for 2044 notes buyback](https://longbridge.com/en/news/295912622.md)
- [Reckitt self-care chief says AI boosts access to health information, strengthens consumer trust](https://longbridge.com/en/news/293745475.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [DE: 3Q 2026 saw sales and profit growth, but FY 2026 guidance signals industry headwinds](https://longbridge.com/en/news/296475895.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**